Canada’s Plan to Optimize Prescription Drug Use
Canada’s Drug Agency (CDA-AMC) has introduced a comprehensive five-year plan, A Prescription for Action: A Pan-Canadian Strategy for Advancing the Appropriate Use of Prescription Medications, aimed at enhancing the safe and effective use of prescription drugs across Canada. This strategy seeks to improve health outcomes, reduce risks, and promote a sustainable health care system through collaboration and evidence-based initiatives.
Why Appropriate Use Matters
Prescription medications are vital for managing diseases, improving quality of life, and reducing hospitalizations. However, inappropriate use—such as incorrect prescribing, misuse, or lack of tailored treatment—can lead to adverse effects, including side effects, negative health outcomes, or even death. Appropriate use involves patients, caregivers, and health care professionals working together to select medications that align with individual needs and health goals for optimal results.
Core Pillars of the Strategy
The strategy is built on four interconnected priorities to drive meaningful change:
- Partnerships and Program Development
Collaborate with partners nationwide to develop and implement initiatives that promote appropriate medication use. - Connection and Communication
Strengthen networks among stakeholders and provide clear, accessible information to support informed decision-making. - Evidence-Informed Strategy and Policy
Offer decision-makers evidence-based recommendations to shape effective policies and programs. - Evaluation and Transparency
Assess the impact of initiatives and communicate results to ensure accountability and continuous improvement.
By amplifying existing efforts and fostering collaboration, the strategy aims to expand the reach and impact of appropriate use initiatives across Canada.
A Collaborative Approach
Developed through extensive consultation, the strategy reflects input from diverse groups, including:
- Provincial and territorial representatives
- Indigenous health care professionals
- Equity-deserving communities
- Patients and the public
- Prescribers and health system partners
This inclusive process ensures the strategy addresses the needs and priorities of those most affected, empowering Canadians to make informed medication choices, equipping clinicians with evidence-based tools, and guiding policymakers to strengthen the health system.
Background and Development
In 2023, Health Canada’s Canadian Drug Agency Transition Office established an Appropriate Use Advisory Committee, which laid the groundwork for this strategy with its recommendations. That same year, the Government of Canada expanded CDA-AMC’s mandate to focus on improving appropriate prescribing and use of medications to enhance patient health and system sustainability. Ongoing collaboration with the agency’s own Advisory Committee and partners continues to drive progress toward these shared goals.
Voices of Leadership
“This strategy is a testament to collaboration and evidence-based action. By prioritizing the voices of those most impacted, we’re building a foundation for better health outcomes and a stronger health system.”
— Suzanne McGurn, President and CEO, Canada’s Drug Agency
“The Appropriate Use Advisory Committee played a pivotal role in shaping this strategy. This is just the beginning—a shared commitment to measurable results and improved health for Canadians.”
— Stephen Samis, Co-Chair, Appropriate Use Advisory Committee
About Canada’s Drug Agency
Canada’s Drug Agency (CDA-AMC) is a pan-Canadian health organization funded by federal, provincial, and territorial governments. Tasked with enhancing coordination and value in Canada’s drug and health technology landscape, CDA-AMC provides independent evidence and advice to health system leaders. Through national and international partnerships, the agency works to improve decision-making and drive better health outcomes.
